Jazz Pharmaceuticals (JAZZ) stock gains as its lung cancer therapy Zepzelca, in combination with Roche's Tecentriq, receives ...

Citius Oncology, Inc. ("Citius Oncology") , the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") , a late-stage biopharmaceutical company developing and commercializing ...

Intellectus Partners LLC recently doubled down on Regeneron Pharmaceuticals, upping its stake by 92.7% in Q1. The firm now ...

The Federal Circuit recently considered the scope of a permanent injunction that prohibited a drug manufacturer from ...

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Detailed price information for Jazz Pharma Plc (JAZZ-Q) from The Globe and Mail including charting and trades.

Jazz Pharma's Zepzelca plus Tecentriq significantly improved survival in a Phase 3 study for extensive-stage small-cell lung ...

Analysts said the data suggest “a strong treatment effect.” Jazz has filed for FDA approval for the combination, which could ...

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced today that the Phase 3 IMforte trial has established a new milestone in the ...

Jazz Pharmaceuticals (NASDAQ:JAZZ) said on Monday that the company's late-stage study of Zepzelca in combination with ...